Oxide terpenes as human skin penetration enhancers of haloperidol from ethanol and propylene glycol and their modes of action on stratum corneum

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 2, 2003, Pages 220-228

  Vaddi, Haranath Kumar ^a   Ho, Paul Chi Lui ^a   Chan, Yew Weng ^b   Chan, Sui Yung ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Enhancement mechanism; Haloperidol; Permeation; Solvent; Terpene

Indexed keywords

ALCOHOL; HALOPERIDOL; PENETRATION ENHANCING AGENT; PROPYLENE GLYCOL; SOLVENT; TERPENE DERIVATIVE; OXIDE; TERPENE;

ARTICLE; BILAYER MEMBRANE; CHEMICAL BINDING; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BINDING; DRUG PENETRATION; EXTRACTION; FEMALE; FLUIDIZATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; PREDICTION; SKIN PENETRATION; STRATUM CORNEUM; CHEMISTRY; DRUG EFFECT; EPIDERMIS; METABOLISM; PHYSIOLOGY; SKIN ABSORPTION;

EPIDERMIS; ETHANOL; FEMALE; HALOPERIDOL; HUMANS; OXIDES; PROPYLENE GLYCOL; SKIN ABSORPTION; TERPENES;

EID: 0042768142     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.26.220     Document Type: Article

References (30)

1. Godwin D. A., Michniak B. B., Drug Dev. Ind. Pharm., 25, 905-915 (1999).
2. Williams A. C., Barry B. W., Pharm. Res., 8, 17-24 (1991).
3. Obata Y., Takayama K., Machida Y., Nagai T., Drug Design & Discovery, 8, 137-144 (1991).
4. Gao S., Singh J., J. Control. Release., 51, 193-199 (1998).
5. Levang A. K., Zhao K., Singh J., Int. J. Pharmaceut., 181, 255-263 (1999).
6. Chattaraj S. C., Walker R. B., "Percutaneous Penetration Enhancers," ed. by Smith E. W., Maibach H. I., CRC Press, New York, 1995, pp. 5-15.
7. Levison K. K., Takayama K., Isowa K., Okabe K., Nagai T., J. Pharm. Sci., 83, 1367-1372 (1994).
8. Cornwell P. A., Barry B. W., Stoddart C. P., Bouwstra J. A., J. Pharm. Pharmacol., 46, 938-950 (1994).
9. Naik A., Guy R. H., "Mechanisms of Transdermal Drug Delivery," ed. by Potts R. O., Guy R. H., Marcel Dekker, New York, 1997, pp. 87-149.
10. Vaddi H. K., Wang L. Z., Ho P. C., Chan S. Y., Int. J. Pharmaceut., 212, 247-255 (2001).
11. Vaddi H. K., Wang L. Z., Ho P. C., Chan Y. W., Chan S. Y., Chem. Pharm. Bull., 49, 1395-1400 (2001).
12. Megrab N. A., Williams A. C., Barry B. W., Int. J. Pharmaceut., 116, 101-112 (1995).
13. Kligman A. M., Christophers E., Arch. Dermatol., 88, 702-705 (1963).
14. Wester R. C., Maibach H. I., Sedik L., Melendres J., Fundam. Appl. Toxicol., 19, 1-5 (1992).
15. Okamato H., Komatsu H., Hashida M., Sezaki H., Int. J. Pharmaceut., 30, 35-45 (1986).
16. Almirall M., Montana J., Escribano E., Obach R., Berrozpe J. D., Drug Res., 46, 676-680 (1996).
17. Forsman A., Ohman R., Curr. Ther. Res., 20, 319-336 (1976)
18. Reynolds J. E. F., "Martindale The Extra Pharmacopoeia," 31st ed., The Pharmaceutical Press, London, 1996, pp. 714-715.
19. Lewis R. N. A. H., Mc Eelhaney R. N., "Infrared Spectroscopy of Biomolecules," ed. by Mantsch H. H., Chapman D., Wiley-Liss, New York, 1996, pp. 159-202.
20. Harrison J. E., Groundwater P. W., Brain K. R., Hadgraft J., J. Control. Release, 41, 283-290 (1996).
21. Yamane M. A., Williams A. C., Barry B. W., Int. J. Pharmaceut., 116, 237-251 (1995).
22. Cornwell P. A., Barry B. W., Int. J. Pharmaceut., 94, 189-194 (1993).
23. Barry B. W., J. Control. Release, 6, 85-97 (1987).
24. Golden G. M., Guzek D. B., Harris R. R., McKie J. E., Potts R. O., J. Invest. Dermatol., 86, 255-259 (1986).
25. Cornwell P. A., Barry B. W., Bouwstra J. A., Gooris G., Int. J. Pharmaceut., 127, 19-26 (1996).
26. Francoeur M. L., Golden G. M., Potts R. O., Pharm. Res., 7, 621-627 (1990).
27. Cuyper H. D., Bollen J., Praag H. M. V., Verstraeten D., Br. J. Psychiatry., 148, 560-566 (1986).
28. Leopold C. S., Lippold B. C., J. Pharm. Pharmacol., 47, 276-281 (1995).
29. Moghimi H. R., Williams A. C., Barry B. W., J. Pharm. Pharmacol., 50, 955-960 (1998).
30. Cornwell P. A., Barry B. W., J. Pharm. Pharmacol., 46, 261-269 (1994).